Compare Tencent Music Entertainment Group - ADR (TME) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tencent Music Entertainment Group - ADR vs Vertex Pharmaceuticals Incorporated — how do they compare? Tencent Music Entertainment Group - ADR trades at $8.41 (market cap $16.09B), while Vertex Pharmaceuticals Incorporated trades at $526.41 (market cap $134.25B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.3× Tencent Music Entertainment Group - ADR's market cap, and Tencent Music Entertainment Group - ADR pays a 2.75% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| TME | VRTX | |
|---|---|---|
Market Cap | $16.09B | $134.25B |
Sector | Media | Health |
52-Week High | $26.36 | $529.65 |
52-Week Low | $8.16 | $376.62 |
Enterprise Value | $14.05B | $128.37B |
Dividend Yield | 2.75% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tencent Music Entertainment (TME) is trading at $8.38, down 15.35% amid mixed Q2 2026 results that showed revenue growth but profit beat expectations. The stock faces bearish technical signals with oversold RSI conditions, while fundamentals remain strong with 33.6% net margin and attractive valuation at 10.29 P/E. Recent news highlights slowing operational growth and competitive pressures, though institutional activity shows mixed positioning with some funds increasing stakes while others reduce exposure.
TME presents a value opportunity with solid profitability and cash flow generation, but near-term headwinds include intensifying competition, AI-related copyright challenges, and slowing user growth. Analyst consensus leans neutral with 45.8% buy ratings, suggesting cautious optimism for long-term investors willing to navigate current volatility.
Vertex Pharmaceuticals (VRTX) trades at $526.33, up 0.46% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with 2025 revenue of $12.0B and net income of $3.95B, though recent Q2 2026 earnings slightly missed estimates. Analyst sentiment remains positive with an 83.9% buy rating and a $534.25 consensus price target, while news highlights raised 2026 sales guidance driven by cystic fibrosis drug strength and newer product launches.
The outlook for VRTX is favorable given robust revenue growth, high profitability margins, and raised full-year guidance. Key opportunities include diversification beyond cystic fibrosis with newer products, but risks involve earnings volatility, competitive pressures, and execution on pipeline developments. The stock's valuation at a P/E of 30.85 requires sustained growth to justify further upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tencent Music Entertainment Group - ADR
TME is the largest online music service provider in China. It was founded in 2016 with the business combination of QQ Music (founded in 2005), Kuwo Music (founded in 2005) and Kugou Music (founded in 2004) streaming platforms. Tencent is the largest shareholder of TME with over 50% shares and over 90% voting rights held. TME also provides social entertainment services, including music live audio/video broadcasts and online concert services through the three platforms mentioned above, and online karaoke through an independent platform WeSing.
Read more on TME →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
